Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada

    AURORA, Ontario, Sept. 23 /CNW/ -- Helix BioPharma announced today that
Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., will be
presenting L-DOS47 research findings at the National Research Council of
Canada's (NRC) Eighth Annual General Meeting of the Genomics and Health
Initiative, today in Saskatoon, Saskatchewan, Canada.  The meeting includes
Canadian researchers from across the NRC, government departments and private
industry and covers diverse topics in genomics research.
    Dr. Chao's presentation, titled "L-DOS47: Targeting the Tumor
Microenvironment with an Immunoconjugate" will provide a summary of selected
previously announced L-DOS47 research findings.  "We are very pleased to have
been invited to participate in this important scientific forum," said Dr.
Chao.  "It is an excellent opportunity to showcase our findings to Canada's
research community as we continue to advance our L-DOS47 development program.
    For additional information on the Genomics and Health Initiative
conference, please visit:  http://www.pbi.nrc.ca/ghi-agm.htm .
    About L-DOS47
    L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody, to form a potential new targeted drug
product for the treatment of adenocarcinoma of the lung, the most common form
of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer
effect. It is based upon a naturally occurring enzyme called urease that
essentially reverses the urea cycle by breaking down urea into metabolites
that include ammonia and hydroxyl ions. By doing so at the site of cancerous
tissues in the body, L-DOS47 is believed to modify the microenvironmental
conditions of lung cancer cells in a manner that leads to their death. Among
these theorized effects, L-DOS47 is  believed to stimulate an increase in the
pH of the microenvironment surrounding the cancerous cells, effectively
reversing the acidic extra-cellular conditions that are known to be necessary
for cancer cell survival. As well, the local production of ammonia at the site
of cancerous tissues is thought to readily diffuse into the cancer cells to
exert a potent cytotoxic effect by interfering with their critical metabolic
    About Helix BioPharma Corp.
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha- 2b and its novel L-DOS47 new drug candidate. Helix is listed
on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone
    Russo Partners LLC
    Tel:  (619) 814-3510
    Fax:  (619) 955-5318
    Email:  ian.stone@russopartnersllc.com

    David Schull
    Russo Partners LLC
    Tel:  (212) 845-4271
    Email:  david.schull@russopartnersllc.com
    Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept
responsibility for the adequacy or accuracy of the content of this News
Release.  This News Release contains certain forward-looking statements and
information regarding the Company's activities, which statements and
information can be identified by the use of forward-looking terminology such
as "believed", "continue", "developing", "potential", or variations thereon,
or comparable terminology referring to future events or results. Forward
looking statements and information are statements and information about the
future and are inherently uncertain. Helix's actual results could differ
materially from those anticipated in these forward-looking statements and
information as a result of numerous risks and uncertainties including without
limitation: uncertainty whether L-DOS47 will be successfully developed and
commercialized as a drug or at all; the need for additional clinical trials,
the occurrence and success of which cannot be assured; product liability and
insurance risks; research and development risks, the risk of technical
obsolescence; the need for further regulatory approvals, which may not be
obtained in a timely matter or at all; intellectual property risks;
marketing/manufacturing and partnership/strategic alliance risks; the effect
of competition; uncertainty of the size and existence of a market opportunity
for Helix's products; as well as a description of other risks and
uncertainties affecting Helix and its business, as contained in news releases
and filings with the Canadian Securities Regulatory Authorities, including its
latest Annual Information Form, at www.sedar.com, any of which could cause
actual results to vary materially from current results or Helix's anticipated
future results. Forward-looking statements and information are based on the
beliefs, opinions and expectations of Helix's management at the time they are
made, and Helix does not assume any obligation to update any forward-looking
statement or information should those beliefs, opinions or expectations, or
other circumstances change, except as required by law.

For further information:

For further information: Investor & Media Relations, Ian Stone,
+1-619-814-3510, fax, +1-619-955-5318, ian.stone@russopartnersllc.com, or
David Schull, +1-212-845-4271, david.schull@russopartnersllc.com, both of
Russo Partners LLC for Helix BioPharma Web Site:

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890